Janus Henderson Group Portfolio holdings
Janus Henderson Group, formed in 2017 through the merger of Janus Capital Group (founded 1969) and Henderson Group (founded 1934), is a global asset management firm headquartered in London, managing over $350 billion in assets as of late 2024 for institutional, retail, and high-net-worth clients. With a strong presence in the U.S., Europe, and Asia-Pacific, the firm offers a wide range of investment products, including equities, fixed income, multi-asset, and alternative strategies, often blending active management with research-driven insights. Known for its equity expertise from Janus’s growth-focused heritage and Henderson’s European fixed-income strengths, Janus Henderson serves clients through mutual funds, ETFs, and bespoke portfolios, emphasizing risk-adjusted returns and ESG integration. Led by CEO Ali Dibadj since 2022, the publicly traded firm (NYSE: JHG) continues to refine its strategy amid competitive pressures, maintaining a foothold in key markets worldwide.
Top Buys
| 1 |
Rentokil
RTO
|
$510M |
| 2 |
Apellis Pharmaceuticals
APLS
|
$205M |
| 3 |
TFI International
TFII
|
$146M |
| 4 |
Ambev
ABEV
|
$133M |
| 5 |
Vanguard S&P 500 ETF
VOO
|
$132M |
Top Sells
| 1 |
Microsoft
MSFT
|
$8.38B |
| 2 |
Apple
AAPL
|
$5.18B |
| 3 |
Mastercard
MA
|
$3.67B |
| 4 |
Alphabet (Google) Class C
GOOG
|
$3.38B |
| 5 |
Amazon
AMZN
|
$3.16B |
Sector Composition
| 1 | Technology | 28.11% |
| 2 | Healthcare | 21.42% |
| 3 | Financials | 11.42% |
| 4 | Industrials | 10.68% |
| 5 | Consumer Discretionary | 10.04% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
151
RB Global
RBA
$21.5B
| $220M | 0.16% |
3,797,138
-3,841,206
| -50% | -$222M |
|
152
United Therapeutics
UTHR
$17.2B
| $213M | 0.15% |
767,426
-882,216
| -53% | -$245M |
|
153
Parker-Hannifin
PH
$95.9B
| $212M | 0.15% |
727,269
-733,129
| -50% | -$213M |
|
154
AstraZeneca
AZN
$254B
| $207M | 0.15% |
3,051,691
-3,740,185
| -55% | -$254M |
|
|
155
Apellis Pharmaceuticals
APLS
$3.62B
| $206M | 0.15% |
3,987,745
+3,959,473
| +14,005% | +$205M |
|
156
Alliant Energy
LNT
$16.6B
| $201M | 0.14% |
3,644,956
-3,642,740
| -50% | -$201M |
|
157
Union Pacific
UNP
$132B
| $200M | 0.14% |
968,211
-142,339
| -13% | -$29.5M |
|
158
Tyler Technologies
TYL
$24B
| $198M | 0.14% |
614,596
-676,228
| -52% | -$218M |
|
159
Canadian Natural Resources
CNQ
$65.2B
| $198M | 0.14% |
7,116,346
-7,711,206
| -52% | -$214M |
|
160
Gildan
GIL
$8.21B
| $196M | 0.14% |
7,167,979
-7,112,377
| -50% | -$195M |
|
161
Visteon
VC
$3.42B
| $194M | 0.14% |
1,485,204
-2,036,390
| -58% | -$266M |
|
162
Regal Rexnord
RRX
$9.78B
| $193M | 0.14% |
1,608,256
-2,070,066
| -56% | -$248M |
|
163
Amgen
AMGN
$151B
| $192M | 0.14% |
732,534
+257,862
| +54% | +$67.7M |
|
164
Icon
ICLR
$13.7B
| $192M | 0.14% |
986,564
-1,046,692
| -51% | -$203M |
|
165
Autodesk
ADSK
$68.1B
| $191M | 0.14% |
1,021,643
-1,198,115
| -54% | -$224M |
|
166
Hasbro
HAS
$11.3B
| $191M | 0.14% |
3,128,219
-5,598,877
| -64% | -$342M |
|
167
Uber
UBER
$192B
| $190M | 0.14% |
7,676,669
-10,984,749
| -59% | -$272M |
|
168
Sensient Technologies
SXT
$4.79B
| $190M | 0.14% |
2,600,023
-2,471,815
| -49% | -$180M |
|
169
Oracle
ORCL
$626B
| $189M | 0.13% |
2,306,858
-3,141,138
| -58% | -$257M |
|
170
Cognizant
CTSH
$34.9B
| $185M | 0.13% |
3,240,241
-1,694,647
| -34% | -$96.9M |
|
171
Rockwell Automation
ROK
$38.4B
| $185M | 0.13% |
718,041
-651,465
| -48% | -$168M |
|
172
Akero Therapeutics
AKRO
$3.52B
| $183M | 0.13% |
3,340,174
-5,210,744
| -61% | -$286M |
|
173
Casey's General Stores
CASY
$18.5B
| $181M | 0.13% |
806,873
-1,032,983
| -56% | -$232M |
|
174
Pfizer
PFE
$140B
| $181M | 0.13% |
3,524,312
-3,772,426
| -52% | -$193M |
|
175
Regeneron Pharmaceuticals
REGN
$60.1B
| $178M | 0.13% |
247,022
-323,524
| -57% | -$233M |
|